论文部分内容阅读
目的评价11C-METPET/CT脑显像对判断脑胶质瘤复发的临床应用价值。方法28例脑胶质瘤手术切除后患者,临床怀疑复发行11C-METPET/CT显像,其中24例同期行FDG PET/CT检查,19例行头颅增强MRI检查,最后诊断根据病理检查和临床随访结果确定。结果28例患者中11C-METPET/CT显像阳性20例,其中1例假阳性;阴性8例,其中假阴性1例,11C-METPET/CT显像的敏感性、特异性和准确率分别为95%、87.5%、92.9%,FDG PET/CT分别为88.9%、50%、79.2%,增强MRI的敏感性、特异性和准确率分别为70%、42.9%、54.9%。结论评价脑胶质瘤复发,11C-METPET/CT较FDGPET/CT和增强MRI有更高的准确性和临床应用价值。
Objective To evaluate the clinical value of 11C-METPET / CT brain imaging in judging the recurrence of glioma. Methods Twenty-eight patients with glioma were enrolled in the study. 11C-METPET / CT imaging was suspected. Among them, FDG PET / CT was performed in 24 cases and cranial enhanced MRI was performed in 19 cases. The final diagnosis was based on pathological examination and clinical Follow-up results to determine. Results Of the 28 patients, 11c-METPET / CT images were positive in 20 cases, of which 1 case was false positive and 8 cases negative. Among them, 1 case had false negative results. The sensitivity, specificity and accuracy of 11C-METPET / CT imaging were 95 %, 87.5%, 92.9% respectively. The FDG PET / CT were 88.9%, 50%, 79.2% respectively. The sensitivity, specificity and accuracy of enhanced MRI were 70%, 42.9% and 54.9% respectively. Conclusion Evaluation of glioma recurrence, 11C-METPET / CT FDG PET / CT and enhanced MRI have a higher accuracy and clinical value.